TY  - CHAP
M1  - Book, Section
TI  - Benign Prostatic Hyperplasia
A1  - Lee, Mary
A1  - Sharifi, Roohollah
A2  - DiPiro, Joseph T.
A2  - Talbert, Robert L.
A2  - Yee, Gary C.
A2  - Matzke, Gary R.
A2  - Wells, Barbara G.
A2  - Posey, L. Michael
PY  - 2017
T2  - Pharmacotherapy: A Pathophysiologic Approach, 10e
AB  - Patient  Care  Process  for  the  Management  of  Benign  Prostatic  Hyperplasia  (BPH)CollectPatient  characteristics  (e.g.,  age,  race)Patient  history  (past  medical  history,  family  history,  social—tobacco,  recreational  drug,  or  alcohol  use)Presence  of  obstructive  and/or  irritative  bladder  symptoms  and  their  impact  on  patient  lifestyle  and  health-related  quality  of  life  (see  Clinical  Presentation  box)Patient's  perception  of  bothersomeness  of  voiding  symptoms  using  AUA  Symptom  Score  (see  Diagnostic  Evaluation  section)Current  and  past  medications,  including  prescription  and  nonprescription  medications;  nonpharmacologic  interventions  for  BPH;  and  medications  perceived  to  cause  or  worsen  BPH  (see  Medication-Related  Symptoms  section)Objective  data  (see  Diagnosis  section  and  Clinical  Presentation  box)Blood  pressure,  heart  rate,  height,  weight,  and  BMIDigital  rectal  examinationLabs  (e.g.,  urinalysis,  blood  urea  nitrogen  and  serum  creatinine,  prostate-specific  antigen)Urinary  flow  rates  and  postvoid  residualAssessDisease  severity  (see  Table  84-1);  patient  views  on  watchful  waiting  (in  mild  cases),  medical  treatment  (in  moderate  to  severe  cases),  and  surgery  (in  severe  cases)Need  for  further  evaluation  based  on  laboratory  and  examination  findingsSize  of  prostate  by  digital  rectal  exam  or  transrectal  ultrasound  of  the  prostatePresence  of  BPH  or  other  causes  of  lower  urinary  tract  symptoms  (prostate  cancer,  prostatitis)Presence  of  erectile  dysfunctionPlan*Dietary  and  lifestyle  modifications  to  avoid  problematic  symptoms  and  situations  (see  Medication-Related  Symptoms  section  and  Clinical  Presentation  section)Interventions  to  encourage  heart-healthy  lifestyle,  smoking  cessation  (if  needed),  weight  loss  (if  needed),  and  management  of  other  chronic  diseasesDrug  therapy  regimen  including  specific  agent(s),  dose,  route,  frequency,  and  duration;  specify  the  continuation  and  discontinuation  of  existing  therapies  (see  Figure  84-2  and  Tables  84-2,  84-3,  and  84-4,  and  the  Personalized  Pharmacotherapy  section  of  the  text),  advantage  or  disadvantage  of  single  drug  versus  combination  therapyMonitoring  parameters  including  efficacy  (symptom  relief)  and  safety  (medication-specific  adverse  effects)  (see  Table  84-5)Patient  education  (e.g.,  purpose  of  treatment,  dietary  and  lifestyle  modification,  drug  therapy)Comparison  of  before  and  during  treatment  response  by  repeating  AUA  Symptom  Score  or  using  a  voiding  diary  (see  Diagnostic  Evaluation  section)Referrals  to  other  providers  when  appropriate  (e.g.,  physician,  urologist)Implement*Provide  patient  education  regarding  all  elements  of  treatment  plan  Use  motivational  interviewing  and  coaching  strategies  to  maximize  adherenceSchedule  follow-up  at  6–12  months  for  watchful  waiting  and  at  shorter  intervals  in  those  under  treatment  or  being  considered  for  surgical  interventionFollow-up:  Monitor  and  EvaluateAssess  patient  satisfaction  with  relief  of  symptomsPresence  of  adverse  effectsPatient  adherence  to  treatment  plan  using  multiple  sources  of  information*Collaborate  with  patient,  caregivers,  and  other  health  professionals  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/18
UR  - accesspharmacy.mhmedical.com/content.aspx?aid=1148578015
ER  -